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INTRODUCTION
The existence of tumor specific antigens in animal systems has now been well
established and reviewed (1-4). Although definitive proof of the specificity of such
antigens in human tumors has been lacking, there is evidence that tumor associated
antigens also exist in humans (5-7); these antigens have now been demonstrated in
such human tumors as Burkitt's lymphoma (8, 9), carcinoma of the colon (10),
neuroblastoma (11), sarcomas (12-14), and melanoma (15). These studies have
also revealed that human subjects do mount an immunologic reaction against their
tumors.
Since this paper concerns immunologic studies of human melanoma, it will be
appropriate to review several clinical features in the natural history of melanoma,
which appear to have clear relevance to the host response to this particular neo-
plasm: 1. Convincing demonstrations of cases occasionally undergoing spon-
taneous regression of primary melanoma (16-18), or partial regression of primary
cutaneous melanoma (19), or regression of isolated metastatic nodules (20), and
the commonly encountered feature characterized by long disease free interval in
many patients (21) are all suggestive of some host defense mechanism against
their tumors.
2. The auto-destruction of melanotic tumors in the so-called benign "halo
nevus" and the occurrence of similar phenomenon noted at times with malignant
melanoma also attest to the existence of host immune mechanism against autolo-
gous tumor.
3. Further suggestion of host interaction against melanoma may be derived from
the frequent histologic evidence of mononuclear cellular infiltrate around tumor
nodules (22). In addition, approximately 10% of the patients with metastatic
melanoma presents with no identifiable primary site. Some of these patients, how-
ever, report spontaneous involution of pre-existing "moles." Biopsy of these pre-
sumably cryptic primary sites has revealed mononuclear cellular infiltration but
no residual tumor (15).
Besides indirect evidence for tumor immunity in melanoma, more direct evidence
for characteristic antigens related to different constituents of melanoma cells, and
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circulating antibody directed against such antigens, have been independently re-
ported by several authors over the last 5 yr (23-29). Circulating antibody with
cytotoxic property against melanoma cells was demonstrated by Lewis et al. (23)
and subsequently by Grey et al. (24) in a complement-dependent, in vitro test
system. Using immunofluorescence technique, several authors (26-29) have subse-
quently confirmed the presence of circulating antibody against cytoplasmic, nuclear,
or cell membrane antigens. Though there were differences in the seroepidemiologic
data regarding the incidence of antibody in homologous sera, from a consensus
of major studies, several general conclusions can be made: 1. characteristic intra-
cellular and membrane bound (cell surface) antigens are detectable in melanoma
cells with appropriate experimental technique, 2. autologous sera react with their
respective cell constituent antigens more frequently than homologous sera, and 3.
incidence and the titre of circulating antibody appear to correlate with extent and
stages of the disease (30).
The purpose here is to review some of the major immunologic studies in mela-
noma and present relevant data from our work in the field of humoral and cell
mediated immunity in malignant melanoma.
DETECTION OF TUMOR RELATED ANTIGEN AND CIRCULATING
ANTIBODY IN MALIGNANT MELANOMA
A tumor associated soluble antigen capable of stimulating both autochthonous
and allogeneic lymphocytes from melanoma patients was detected earlier in this
laboratory (25) in the cyst fluid from a necrotic melanoma. This substance was
found to be an electrophoretically homogeneous protein with the mobility of a beta
globulin. An immunochemically identical substance was isolated from the urine
and tumor tissues from three patients. Rabbit antiserum prepared against the
lymphocyte stimulating substance reacted with the tumor cell protein and its plasma
and urinary counterpart, when tested by Ouchterlony gel diffusion technique.
In a subsequent study (31) we reported that following dimethyl triazeno
imidazole carboximide (DTIC) therapy the circulating antigen disappeared from
patient's serum when studied on starch block electrophoresis. Posttreatment lym-
phocytes responded strikingly to pretherapy tumor fluid, however, marked reduction
in stimulation was noted when such lymphocytes were incubated with posttherapy
tumor fluid. Also, lymphocytes from five other melanoma patients were also stimu-
lated by the pretreatment tumor fluid, while marked reduction in this cross-reactiv-
ity was noted with posttherapy fluid. These studies suggested the presence of a
cross-reacting tumor associated antigen and inhibition of its synthesis upon treat-
ment with DTIC.
Subsequently, an indirect membrane-immunofluorescence technique has been
employed to detect membrane-bound antigen in melanoma cells and circulating
humoral immunity against such antigen. Tissue cultures are maintained in mono-
layer in Ham's F-10 media (Gibco) supplemented by 20% fetal calf serum
(Gibco). All cultures are periodically tested for mycoplasma contamination. Tryp-
sinized cells (1 X 105) are incubated in microfuge tubes with test serum (in de-
sired concentration) for %2 hr at 370C after which the cells are washed inphosphate
buffered saline three times, and incubated with a commercially available (Hyland)
fluorecein isothiocyanate labeled antihuman globulin (1:20) for another % hr at
370C. The cells are again washed, resuspended in 20% glycerol, mounted on glass
slides, and read for specific membrane immunofluorescence. A positive reaction
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FIG. 1. Membrane immunofluorescent photomicrographs of melanoma cells grown in serial
tissue culture (la), and after heterotransplantation (lb). The cell in serial tissue culture
demonstrates discrete areas of fluorescence (la), whereas a complete ring of fluorescence
is observed on the cell derived from transplanted tumor explant (lb).
is characterized by discrete sites of bright apple-green fluorescence or a complete
ring of fluorescence (see heterotransplantation section) along the cell membrane
(Fig. 1). A diffuse bright green staining is considered indicative of cell death. An
immunofluorescence index (I.F. index) is calculated by the following formula: I.F.
index = mean proportien of unstained cells with normal control serum minus the
proportion of unstained cells with test serum, divided by the former number. An
I.F. index of 0.3 or more is considered positive.
Autologous sera react almost always with their tumor cells in culture, whereas
positive reaction is noted in 40% of the homologous sera from melanoma patients
when tested on one of our reference melanoma cell lines. When a panel of positive
sera is tested against several other melanoma cell lines, positive reaction is always
noted with some of the reference sera against one or the other line but never
consistently with all of them.
Characteristic individual specificity in melanoma antigen. Serologic specificity
of the antimelanoma antibody has been previously documented with the usual
methods of testing positive reference sera against established culture lines derived
from other malignancies (where such tests have been found negative), and also
by absorption study where other cell lines, including cells from benign nevi, have
been shown to fail to absorb the reactivity from the positive reference sera when
cultured melanoma cells successfully did so (27, 28).
Thus, available data and the results of our study suggest that antigens with tumor
related specificity are often shared by melanomas from different patients. It is ap-
parent, however, that beside this shared cell surface antigen, individual specificity
of cell surface antigen in melanoma also does exist. This is evident from our data
and the data of others that while the incidence of circulating antibody against
melanoma antigen varies from 40% to 61% in different series, the reactivity (by
I.F.) approaches 100% with autochtonous sera. This individual specificity in mem-
brane antigen in melanoma has also been shown by Lewis et al. (30) with an in
vitro, antibody mediated cytotoxicity test. Since antigens bound to cell surface are
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capable of eliciting host response that may lead to eventual destruction of tumot
cells, these individual specificities of cell membrane antigen are crucial in host de-
fense against melanoma.
Relation between circulating antibody and prognosis in malignant melanoma.
It has been suggested that incidence and level of antimelanoma antibody correlate
with stage of disease (32). Cytotoxic antibody was detectable by Lewis et al. (23,
30) in patients who had only localized disease, while such antibody could not be
found in patients with widespread metastatic melanoma. The decline of anti-
melanoma antibody was found to parallel the progression of disease from localized
to generalized form. A reversal of this phenomenon was further demonstrated by
the same authors as inoculation of irradiated autogolous tumor cells following ex-
tensive removal of disseminated tumor was found to convert seronegative patients
to seropositive (by cytotoxicity test). In a subsequent study (33) they demon-
strated that sera from seronegative patients (prior to immunization with irradiated
autologous cells) contained a "blocking agent," an IgG, which interacted with the
antibody (also an IgG) in the postimmunized sera. It should be noted that this
phenomenon (where the "blocking agent" was directed against another cytotoxic
antibody, or perhaps against an antigen-antibody complex), differed fundamentally
from those described in lymphocytotoxicity or colony-inhibition studies (34, 35),
where such blocking factor(s) are believed to be directed against the tumor anti-
gen. The phenomenon of loss of humoral immunity is, however, somewhat reminis-
cent of similar phenomenon of reversible gain or loss of TL antigen (antigenic
modulation) in mouse leukemia (36). It is not possible to determine whether the
loss of antibody is the cause or the consequence of progression of disease, nor
is it known whether induction of antibody by such immunization will have favor-
able or adverse influence on tumor growth, particularly since the phenomenon of
immunologic enhancement is well established in experimental tumor system (37).
Further studies are warranted for better understanding of the implication of shared
versus individually specific surface antigen, and for identification of the circum-
stances leading to the formation of the so-called blocking factor(s), both of which
will have important bearing on the design of immunotherapy.
CELL MEDIATED IMMUNITY IN MELANOMA
Thus far the discussion has been limited to the humoral immunity in melanoma.
Humoral immunity, however, is a relatively ineffective host defense against most
tumors and (though not conclusively proven in humans yet) may, in effect, block
tumor rejection and cause immunologic enhancement. The evidence thus far
strongly indicates that the cell mediated immunity (CMI) is the principle effector
mechanism in immune defense against cancer. Thymus derived lymphocytes, be-
lieved to be the major participants in CMI, are primarily involved in rejection of
both tumor homograft and naturally occurring tumors (8, 38-41). The two rejec-
tion processes indeed appear to be mediated through the same principle. The
homograft rejection being initiated by tumor specific transplantation antigens
(TSTA) and the immune response against spontaneous tumors is also believed to
be initiated by tumor specific antigens (both the TSTA in animal tumor and tumor
specific antigen in human tumor are, by definition, neoantigens). From their work
on cell mediated immunity in various human tumors the Hellstroms (39) have
offered an analogy between TSTA and tumor specific antigens in human tumors.
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Obviously, transplantation experiments with human tumor is not a realistic possi-
bility, yet autotransplantation and homotransplantation studies (42, 43) have been
conducted in humans and it has been shown that "takes" of such transplant is
influenced by patient's cell mediated immune response. To obviate the unrealistic
approach of transplantation experiments, other in vitro experimental techniques
have been adopted for the study of cell mediated immunity in human tumors. For
our purposes we shall confine our discussion to a brief review of some of these
studies in melanoma and describe our own experience. It has been shown that
characteristic delayed hypersensitivity reaction can be elicited in guinea pigs, with
intradermal injection of soluble antigen extracted from chemically induced sar-
coma, when the recipient animal is preimmunized with the same tumor antigen.
Furthermore, selective resistance to such tumor transplant has been shown to cor-
relate with positive dermal hypersensitivity reaction (44, 45). These studies have
led to the general belief that cell mediated immunity against tumors involve delayed
hypersensitivity reaction.
Delayed hypersensitivity type reaction with intradermal injection of cell-free ex-
tracts of malignant melanoma has been demonstrated by Fass et al. (46). Speci-
ficity of this reaction has been established from demonstration of failure to produce
such a reaction with extracts from normal tissue or benign pigmented mole. This
type of delayed hypersensitivity reaction specific to tumor extract has been shown
to correlate with the extent of disease by the authors, who noted positive reaction
specific to tumor extract only in patients having localized disease. Anergy to such
tumor extract according to the authors was not due to generalized anergy, implying
a rather selective defect in response to melanoma antigen.
Besides delayed hypersensitivity against autologous tumor extracts, nonspecific
reaction against common bacterial or fungal antigens, or sensitization with chemical
hapten such as dinitrochlorobenizene (DNCB) has been shown to serve as a prog-
nostic indicator in melanoma where positive reaction has been equated with favor-
able prognosis (47), though an earlier study by Ziegler et al. (48) failed to make
such a correlation, and Pinsky et al. (49) subsequently noted that ability to react
to DNCB sensitization is often preserved in virtually terminal patients with wide-
spread melanoma.
Since the immune lymphocytes are the mediator cells responsible for delayed
hypersensitivity reaction, homograph rejection, and also by implication for tumor
immunity, in vitro experimental techniques have been employed to study the inter-
action between immune lymphocytes and tumor cells. Evidence for selective inter-
action between immune lymphocytes and melanoma target cells has been sought
in a bidirectional manner. On one hand, studies are undertaken to document
characteristic changes in lymphocytes and on the other hand, attempts have been
made to study the consequences of such interaction on the survival of melanoma
target cells (cytotoxicity). Either would be. indicative of cell mediated immune
reaction.
That autologous and sometimes the allogeneic lymphocytes react with melanoma
cells or melanoma cell products has been demonstrated by several authors (50,
51). Using a mixed, lymphocyte tumor cell culture (MLTC) technique Nagel et
al. (51) demonstrated transformation of autologous lymphocytes characterized by
increased DNA synthesis when they were allowed to interact with autochthonous
melanoma cells. As mentioned earlier, lymphocyte transformation study from our
laboratory revealed transformation of both autochthonous and allogeneic lympho-
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cytes from melanoma patients with a soluble antigen extract from the cyst fluid
of a necrotic melanoma (25), indicating cross-reactivity with a common melanoma
antigen. The same antigen was used by Cochran et al. (52) in a leukocyte migra-
tion inhibition study where the authors demonstrated leukocyte migration inhibition
in 10 of 16 disease-free melanoma patients as opposed to 1 of 6 patients with re-
current melanoma and 2 of 16 normal controls. Cochran's study provided further
evidence for measurable cell mediated immunity against melanoma.
Besides the demonstration of changes in lymphocytes observed in the interaction
of lymphocyte and melanoma cell, cytotoxic property of autologous and allogeneic
lymphocytes have been demonstrated by the Hellstroms, using the colony inhibition
technique (40, 53), and more recently by several authors with in vitro lymphocyte
cytotoxicity technique (35, 41, 54, 55). These in vitro microcytotoxicity techniques
are of considerable interest and have offered a unique opportunity to study the
complex interrelationship between humoral and cell mediated immunity in human
tumors.
Microcytotoxicity test for cell mediated immunity. Because of the obvious poten-
tial of in vitro lymphocyte cytotoxicity tests, we have adapted a modification of
Hellstrom's microcytotoxicity technique for assay of cellular immunity in malignant
melanoma. Details of the technique have been described elsewhere (54). In brief,
cultured cells derived from melanoma were used as target cells in 16 mm diam
Linbro plates (100/wells). After allowing the cells to attach (over 18-24 hr incu-
bation) test serum in 1:6 dilution is added for 30 min after which the serum was
removed. Lymphocytes obtained by Woods' technique (56) were then added to
the wells. The plates were incubated on a rocker for an additional 45 min after
which the medium was supplemented with 40% fetal calf serum. Then the plates
were again incubated on a rocker under CO2 for 48-50 hr after which they were
washed and stained. All incubations were conducted in humid chambers at 370C.
Finally the residual viable cells were counted. Appropriate controls were always
included.
Results (Table 1) to date indicate that in vitro lymphocyte mediated cytotoxicity
may decrease with metastatic spread of melanoma. Levels of cytotoxicity (in excess
of 40% ) are seen only in patients free of disease after surgery or chemotherapy.
It should be noted that our data differs from those of Hellstroms (57), who were
only able to show a reduction in the "level" of cell mediated immunity in advanced
cases by titrating the ratio of lymphocytes and tumor cells. The Hellstroms
TABLE 1
% CELL-MEDIATED CYTOTOXICITY (CORRECTED VALUES)
No systemic treatment BCG or chemotherapy (DTIC)
Disease-free Positive control = 40%
or SH 36% AP 59%
regressing AF 44% TH 39%
Median = 40% Median = 47%
JM 83% ME 23% (NC) BR 20%
Progressing D 17/33% KPL 23% CY 0*%
LH 32% ET 0*%
Median = 24/33% GR 35% JB 0*%
Median = 26% (O's excluded)
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TABLE 2
SERUM BLOCKING FACTORS
Absent or negative Positive
Disease-free or regressing 5 0
Progressing 2 5
(Patients without significant CMI excluded from table)
(34, 57) have demonstrated that patients with progressive metastatic disease ex-
hibit a circulating factor in their sera which is capable of blocking autologous and
allogeneic lymphocytotoxicity in vitro. Results of our studies are in agreement with
the Hellstroms. Blocking factor was found to be present in sera from five out of
seven patients with progressing metastatic melanoma where as none of the five
patients clinically free of disease or with regressing tumor exhibited such blocking
factor (Table 2). Interestingly, the Hellstroms (58) have recently reported the
presence of another serum factor that is capable of canceling the blocking property
of sera containing the so called blocking antibody.
It is noteworthy that considerable differences exist in the results of in vitro lym-
phocyte cytotoxicity studies from different laboratories. For example, Currie et al.
(59) failed to demonstrate the presence of any blocking factor in sera from patients
with melanoma and found that autochthonous lymphocytotoxicity in established
melanoma was extremely uncommon. Despite such differences, evidence neverthe-
less is mounting in the literature in favor of a serum blocking factor in bladder
carcinoma (60), in neuroblastoma (12), and in human sarcoma (61), where au-
tologous serum is being shown to inhibit lymphocyte stimulation by autochthonous
sarcoma cells.
It should be emphasized that while serologic methods for the detection of
humoral tumor immunity are relatively well established (62), microcytotoxicity
techniques for the detection of cell-mediated immunity are yet to be uniformly stan-
dardized. The need for standardization of microtest technique for assay of lympho-
cyte cytotoxicity has recently been well articulated by the participants of a work-
shop in human tumor immunology held at Sloan-Kettering Institute for Cancer
Research, New York (63). Investigators representing different institutions worked
with the same materials (target cells, lymphocytes, sera, reagents, etc.). Significant
differences in the results obtained by different investigators were observed. Though
malignant melanoma was not studied in this workshop, the methodologic problems
observed will nevertheless apply for in vitro microtest technique for assay of cell
mediated immunity in any human cancer. Several important problems, such as use
and screening of serum for plating efficiency; use of target cells with reference to
their derivation, need for target cells free of mycoplasma contamination; method
of lymphocyte purification; period of incubation, etc., were discussed at great
length. Recommendations were made that a cooperative effort be undertaken to
standardize some elements in the technique using coded materials supplied through
a central laboratory.
Clearly then, before these techniques can be widely applied by different labora-
tories to obtain reproducible data, these basic problems in the methodology must
be resolved. Fortunately, several laboratories are now working in this direction.
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HETEROTRANSPLANTATION STUDY
WITH MALIGNANT MELANOMA
No satisfactory heterotransplantation model of human melanoma is currently
available. Such a model would offer an experimental system paralleling the in vivo
condition of human melanoma to a far greater degree than do any in vitro systems
and could be useful as a model for various immunologic and immunotherapeutic
studies. For the purpose of establishing an animal heterotransplantation model,
we have attempted to transplant human melanoma in Wistar Furth (WF) rats by
inoculating cultured melanoma cells. Antithymocyte serum (ATS)-treated WF neo-
nates have been inoculated with 1 X 107 melanoma cells subcutaneously on their
day of birth or on the second postnatal day. The recipient neonates are given
further injections of ATS on every other day until tumor nodules become palpable,
after which gradual tapering of ATS administration is made. Palpable tumor
growth on the site of inoculation is usually appreciable on the tenth day (range
7-21) with continued growth thereafter. Serial passage of such transplants in
ATS-treated WF neonates is easily achieved by inoculating finely minced fresh
tumor explants. Three cell lines have been transplanted. The transplanted tumor
exhibits the same histology as the original biopsy tissue from which the cell
line is derived (Fig. 2) and both the transplanted tumor cells and the cultured
cells maintain their aneuploid karyotype.
Membrane immunofluorescence studies have revealed a significant augmentation
of membrane antigenicity on the animal-passaged cells. This is characterized by
a complete, or almost complete, ring of bright fluorescence all around the cell mem-
brane as opposed to isolated discrete sites of immune complexes on the tissue cul-
ture cells when tested under identical experimental conditions (Fig. 1). Of further
interest, the animal-passaged cells tend to lose this antigenic augmentation as these
cells are maintained through continued subcultures. Thus, we believe that the phe-
nomenon of antigenic augmentation by animal passage offers a system for restoring,
preserving and augmenting membrane antigen. Besides immunologic studies, this
model may also be used for chemotherapeutic, cytokinetic or other relevant studies
with melanoma.
HL-A PHENOTYPE WITH MELANOMA PATIENTS
As a part of our study of cell mediated immunity in malignant melanoma, HL-A
typing has been undertaken on lymphocytes from patients with malignant mela-
noma. Initial studies revealed an interesting deficit of the second, sublocus-antigen
series characterized by an absence of HL-A5. The study subsequently has been
extended and the preliminary result with details of the methodology has been pub-
lished (64). Thirty-three patients with melanoma thus far tested have failed to
reveal the presence of HL-A5, as opposed to 24 out of 29 nonmelanoma cancer
patients and 9 out of 62 normal individual controls demonstrating positive HL-A5
(Table 3). Typing data from families of five patients indicate that in one family
the parents carried the HL-A5 antigen, suggesting that the deficiency of HL-A5
in the patient is acquired by deletion or by genetic crossing over. The significance
of this finding of HL-A5 deficiency in melanoma remains obscure, and further
studies are presently underway to examine the relevance of this phenomenon to
malignant melanoma regarding its mode of dissemination or host-immune response
against such tumors.
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FIG. 2. Photograph of human melanoma tumor transplant (2a) in Wistar Furth rat.
The arrow in Fig. 2a represents growth of tumor along the needle track. Figure 2b demon-
strates the histology of the biopsy from which the cell line has been derived and Fig.
2c demonstrates the histology of the transplanted tumor explant. The arrows in Fig 2b
and 2c indicate pigment production in the tumors.
TABLE 3
PROSPECTIVE STUDY OF HL-A5 DEFICIENCY IN MELANOMA
HL-AS5
No. tested + -
Normal control 62 9 53] P = 0.480
Cancer control 29 5 24 P* = 0.017
Melanoma 33 0 33JP = 0.018J
* Fisher's Exact Test.
SUMMARY
The goal of immunologic study of a given neoplasm is twofold. One is to define
the antigenic makeup of the malignant cells and the other is to identify host-defense
mechanisms involving either humoral or cell mediated immunity. Data from studies
reported here has supported the view that tumor-specific or associated antigens are
present in human melanoma as identified by a number of assay systems including
immunofluorescence, lymphoblastogenesis, leukocyte migration inhibition and lym-
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phocytotoxicity. A new system of heterotransplantation which appears to augment
tumor cell membrane antigenicity is a new tool for further immunologic study.
The observation that the HL-A5 sublocus is deleted in melanoma patients may
provide a genetic marker in this tumor system.
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